Males and females aged 12 to 80 with a diagnosis of chronic spontaneous urticaria (hives) for >6 months, may qualify to participate. Looking for Individuals with the presence of itch and hives for >6 consecutive weeks, who are using a defined anti-histamine. Must be naïve to, intolerant of, or an incomplete responder to the drug omalizumab.
Participants will receive investigational medication (active study drug) or placebo, via injection. Study medication and study-related care will be provided at no cost. Reimbursement for study-related expenses will also be provided. Participants must be willing and able to complete a daily symptom e-diary for the duration of the study.
Study participation will last about 40 weeks and involve about 5 visits to the study centre.
Condition or Disease:
Chronic Spontaneous Urticaria
Intervention/Treatment:Drug: Dupilumab SAR231893,Drug: non sedating H1-antihistamine Drug: Placebo,Drug: non sedating H1-antihistamine Drug: Dupilumab SAR231893,Drug: non sedating H1-antihistamine Drug: Placebo,Drug: non sedating H1-antihistamine Drug: Dupilumab SAR231893,Drug: non sedating H1-antihistamine Drug: Placebo,Drug: non sedating H1-antihistamine
Ages Eligible for Study:
6 Years and 80 Years (Child,Adult,Older Adult)
Sexes Eligible for Study:
Study A and C: Participant must be ≥6 years to 80 years of age at the time of signing the informed consent.
Study B: Participant must be ≥12 years (or the minimum legal age for adolescents in the country of the investigational site) to 80 years of age at the time of signing the informed consent
Participants who have a diagnosis of CSU refractory to H1 antihistamines (H1-AH) at the time of randomization defined by
Diagnosis of CSU>6 months prior to screening visit
Presence of itch and hives for >6 consecutive weeks at any time prior to screening visit despite the use of H1-AH during this time period
Using a study defined H1-antihistamine for CSU treatment
During the 7 days before randomization:
UAS7≥16 ISS7≥ 8
Study A and C: omalizumab naïve, Study B; intolerant or incomplete responder to omalizumab
Participants must be willing and able to complete a daily symptom e-Diary for the duration of the study
Participants are excluded from any of the studies if any of the following criteria apply:
Weight is less than 30 kg in adults and adolescents and 15 kg in children aged 6 to<12years
Clearly defined underlying etiology for chronic urticarias other than CSU
Presence of skin morbidities other than CSU that may interfere with the assessment of the study outcomes
Active atopic dermatitis
Severe concomitant illness(es) that, in the investigator’s judgment, would adversely affect the patient’s participation in the study
Active tuberculosis or non-tuberculous mycobacterial infection, or a history of incompletely treated tuberculosis unless documented adequately treated.
Diagnosed active endoparasitic infections; suspected or high risk of endoparasitic infection
Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiprotozoals, or antifungals within 2 weeks before the screening visit and during the screening period
Known or suspected immunodeficiency
Active malignancy or history of malignancy within 5 years before the baseline visit, except completely treated in situ carcinoma of the cervix, completely treated and resolved non-metastatic squamous or basal cell carcinoma of the skin
History of systemic hypersensitivity or anaphylaxis to omalizumab or any biologic therapy, including any excipients
Participation in prior dupilumab clinical study, or have been treated with commercially available dupilumab.
The above information is not intended to contain all considerations relevant to a patient’s potential participation in a clinical trial.